The Weekly Recap 11/14/25: LSI Alumni Achievements Driving Medtech and Healthtech Forward

In a successful week for the medical technology companies in the LSI Alumni community, we saw LSI Alumni secure over $264M in new funding, announce regulatory clearances, enter new partnerships, and much more on the road to LSI USA ’26 in Dana Point (March 16–20).

Augmedics

Received FDA 510(k) clearance for X2™, its next-generation augmented reality (AR) surgical headset for use with the xvision Spine SystemⓇ. Purpose-built for the operating room, X2 enhances visualization, ergonomics, and performance for spine procedures.

Cern

Partnered with HITLAB to advance its light-based, non-drug treatment for recurrent vaginal infections using the Cern Device™, a novel at-home therapy. The collaboration will support validation efforts ahead of FDA review, focusing on usability, safety, and digital health integration.

Clairity

Raised $43M in Series B funding to commercialize Clairity Breast, the first FDA-authorized AI platform that predicts five-year breast cancer risk from a standard mammogram. The financing will also support development of Clairity Breast 3D and Clairity Heart, expanding its predictive imaging platform into cardiovascular disease.

Cognito Therapeutics

Launched the Brain Health Collaboratory with WVU Rockefeller Neuroscience Institute to accelerate real-world adoption of non-drug neurotherapies. The initiative integrates the Spectris device into clinical care to advance treatment for neurodegenerative disease through adaptive, data-driven workflows.

Cornerstone Robotics

Raised $200M in an oversubscribed round to scale global commercialization of the Sentire surgical robot. The company’s autonomous endoscopic robotic surgery platform is designed to ensure consistent, precise movements, minimizing variability and optimizing outcomes.

EBR Systems

Announced that it enrolled the first patients in the WiSE-UP study to evaluate its FDA-approved wireless CRT system. The leadless device delivers left ventricular pacing and works seamlessly with existing pacemakers, defibrillators, or CRT devices that provide right ventricular pacing.

This blog is originally published here: https://www.lifesciencemarketresearch.com/insights/the-weekly-recap-111425-lsi-alumni-achievements-driving-medtech-and-healthtech-forward 

Comments

Post a Comment

Popular posts from this blog

Cover Story: A Page from Ray Cohen’s Playbook: Scaling, Exiting, and Winning in Medtech

With four decades of company-building, IPOs, boardroom leadership, and monumental exits behind him, Raymond W. Cohen has become one of medtech’s most successful operators. But behind the financial wins — including the recent back-to-back $3.7 billion Axonics and $600 million SoniVie acquisitions by Boston Scientific — is a deeper story of Cohen’s contrarian, full-transparency, people-centered, no-BS approach to leadership and strategy. “People crave inspired, authentic, and transparent leadership that thinks big and acts boldly. They want to be enrolled in a vision of what is possible, and be recognized and compensated for creating measurable results, not be fed a bunch of platitudes.” A quote that is classic  Ray Cohen  — blunt, unapologetic, no-nonsense, and grounded in hard-won experience. With more than four decades in medtech, Cohen has done what many aspire to — build, lead, scale, and sell high-stakes, successful ventures with precision and zero fluff. Known for his no-...
Read more

The Weekly Recap 6/13/25: LSI Alumni Achievements Driving Medtech and Healthtech Forward

In a successful week for the medical technology companies in the LSI Alumni community, we saw LSI Alumni secure over $63M in new funds, receive FDA 510(k) clearances, announce an acquisition, and much more as we wind down   LSI Asia  ’25 in Singapore and gear up for  LSI Europe  ’25 in London (September 7–11). Accelus Received FDA 510(k) clearance for the FlareHawk Interbody Fusion System to be safely subjected to MRI scanning in certain conditions. The clearance supports Accelus’s commitment to safe, high-performance spinal solutions and expands imaging options for patients with FlareHawk implants. Aortyx Raised $16M to advance its bioresorbable aortic patch toward first-in-human trials. The funding supports continued development of Aortyx’s minimally invasive, tissue-regenerating solution for aortic dissection and positions the company for clinical entry within two years. Atraverse Medical Closed $29.4M in follow-on financing to scale U.S. commercialization of HOTW...
Read more

Medtech in 2025: Key Insights from Q1 Earnings

  As we venture into Q2 of 2025, the medtech industry continues to navigate challenges while remaining on a positive growth trajectory. The early earnings reports from major medtech companies provide valuable insights into how the sector is performing and where it is heading. Despite the pressures of ongoing macroeconomic uncertainty, the first quarter of 2025 shows a sector that’s resilient, with many companies reporting strong growth across their key divisions. For more information visit here:  https://www.slideshare.net/slideshow/medtech-in-2025-key-insights-from-q1-earnings/279045324
Read more